TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 57506
Drug: bromocriptine 2-5
Normalized name: bromocriptine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: bromocriptine 2-5 mg twice daily from the 10th day of the menstrual cycle for 1-11 months
Study: 57506
Drug: bromocriptine 2-5
Normalized name: bromocriptine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: bromocriptine 2-5 mg twice daily for 186 cycles
Study: 31557329
Drug: Waitlist/Treatment as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist/Treatment as Usual (WL/TAU)
Study: 28562434
Drug: 5-Fluorouracil and
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-Fluorouracil and 5-Aminolevulinic Acid Photodynamic Therapy (5-FU-ALA-PDT)
Study: 28562434
Drug: 5-Aminolevulinic Acid
Normalized name: 5-aminolevulinic acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-Aminolevulinic Acid Photodynamic Therapy (ALA-PDT)
Study: 23784895
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg herbal capsules twice daily
Study: 23784895
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg placebo capsules twice daily
Study: 19386210
Drug: Various treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatments used for EM (specific treatments not detailed in the abstract)
Study: 16749914
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg daily for 3 months
Study: 8872421
Drug: GHRH combined
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH combined with pyridostigmine (PD) (60 and 120 mg orally at -60 min)
Study: 30414260
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 100 U/mL (Gla‐100)
Study: 30278568
Drug: 5% lidocaine
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lidocaine medicated patch (Lignopad)
Study: 27075659
Drug: UCB-MNCs (4-μl
Approvals — FDA: no, EMA: no, PMDA: no
Description: UCB-MNCs (4-μl injections, 1.6 million cells)
Study: 27075659
Drug: UCB-MNCs (8-μl
Approvals — FDA: no, EMA: no, PMDA: no
Description: UCB-MNCs (8-μl injections, 3.2 million cells)
Study: 27075659
Drug: UCB-MNCs (16-μl
Approvals — FDA: no, EMA: no, PMDA: no
Description: UCB-MNCs (16-μl injections, 6.4 million cells)
Study: 27075659
Drug: UCB-MNCs (6.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: UCB-MNCs (6.4 million cells) plus 30 mg/kg methylprednisolone (MP)
Study: 27075659
Drug: UCB-MNCs (6.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: UCB-MNCs (6.4 million cells) plus MP and a 6-week course of oral lithium carbonate (750 mg/day)
Study: 9565250
Drug: Intravenous pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous pentoxifylline treatment (1.5 mg/kg/h)
Study: 7800378
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (30 mg of beta-carotene, 1000 mg of ascorbic acid, and 800 IU of alpha-tocopherol per day for 9 months)
Study: 3377462
Drug: Norfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (400 mg orally twice daily for 4 days)
Study: 3377462
Drug: Theophylline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (200 mg of aminophylline three times daily for 4 days)
Study: 31730832
Drug: COPD Assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: COPD Assessment Test (CAT) administered before and after treatment of acute exacerbations
Study: 28940638
Drug: l-citrulline (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-citrulline (6 g day-1)
Study: 26342424
Drug: RTS,S/AS01 vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01 vaccination with booster dose
Study: 17198101
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia with propofol and remifentanil; maintained constant rates to achieve BIS levels of 40-60 during the procedure
Study: 11292410
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of 15 to 20 mg of crystalline triamcinolone acetonide at the end of surgery
Study: 9380943
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (5 mg) via active matrix
Study: 9380943
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (10 mg) via active matrix
Study: 9380943
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (5 mg) via polyptychial matrix
Study: 9380943
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (10 mg) via polyptychial matrix
Study: 10932442
Drug: Standard hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hospital treatment
Study: 4758446
Drug: Frusemide 2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide 2000 mg daily
Study: 31043522
Drug: Intranasal arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal arginine vasopressin (AVP) treatment (24 IU for ages 6-9.5 years; 32 IU for ages 9.6-12.9 years)
Study: 31043522
Drug: Intranasal arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal arginine vasopressin (AVP) treatment
Study: 25372313
Drug: 810-nm pulsed
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 810-nm pulsed diode laser treatment
Study: 25372313
Drug: Overall score
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall score combining erythema and roughness/bumpiness for treatment
Study: 23834688
Drug: Carvedilol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (up to 0.8 mg/kg/day)
Study: 27444427
Drug: Group CBT
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group CBT (Cognitive Behavioral Therapy)
Study: 19383032
Drug: Vildagliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (50 mg b.i.d.)
Study: 17274272
Drug: Electrolytic carbohydrate
Normalized name: CARBOHYDRATE/ELECTROLYTES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrolytic carbohydrate solution (group GP, n=14)
Study: 29958055
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml normal saline (placebo)
Study: 3060626
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil (CPDX‐PR) 400 mg daily for 7 days
Study: 3060626
Drug: Cefaclor (CCL)
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor (CCL) 750 mg daily for 7 days
Study: 28910139
Drug: Family-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based cognitive-behavioral therapy (CBT), 10 sessions
Study: 25940277
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus a decision aid presenting risks and benefits of different treatments (surgery and radiotherapy)
Study: 24467988
Drug: Delayed antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed antibiotics (control group)
Study: 15663405
Drug: Misoprostol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (400 mug oral + 400 mug intravaginal, repeated every 6 hours for a maximum of five doses)
Study: 11961329
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml tap water with 1.0 mg F
Study: 11961329
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml standard milk with 1.0 mg F
Study: 11961329
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml standard milk
Study: 11961329
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml F‐free tap water
Study: 10874381
Drug: Regular intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular intramuscular (i.m.) injections of opioid analgesia
Study: 8768863
Drug: Antithyroid drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid drugs for 18 months
Study: 8768863
Drug: Radioiodine (iodine-131)
Normalized name: Radioiodine
DrugBank: Iodide I-131 (DB09293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine (iodine-131) treatment
Study: 6416664
Drug: Megavoltage irradiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megavoltage irradiation (general treatment)
Study: 26464453
Drug: 0.06 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06 mg/kg Sildenafil (Sild-L group)
Study: 26464453
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg Sildenafil (Sild-H group)
Study: 22847059
Drug: Rosiglitazone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (8 mg once daily for 6 weeks)
Study: 19625385
Drug: D2‐like agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: D2‐like agonist (Bromocriptine, 1.25 mg)
Study: 19625385
Drug: D2‐like antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: D2‐like antagonist (Sulpiride, 400 mg)
Study: 10456967
Drug: Intradermal method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal method
Study: 26223543
Drug: Adalimumab (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (24 mg/m², maximum dose 40 mg every other week)
Study: 17407516
Drug: Dutasteride 0.5
Normalized name: dutasteride 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5 mg/day for 2 weeks before and after TURP, or 4 weeks before and 2 weeks after TURP
Study: 15184247
Drug: Celecoxib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (100 or 400 mg twice daily)
Study: 2109729
Drug: Terlipressin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin plus sublingual nitroglycerin (group I)
Study: 19415122
Drug: WR279,396 applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: WR279,396 applied twice a day for 20 days
Study: 15543027
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy (combined with estrogen)
Study: 8776361
Drug: Topical potent
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical potent glucocorticoid treatment (betamethasone-17-valerate) applied twice a day for 3 days
Study: 27261995
Drug: Active group
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active group music therapy
Study: 27261995
Drug: Receptive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receptive group music therapy
Study: 12071338
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment in untreated type 1 patients
Study: 12071338
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy adjustment in males aged 16-59 years
Study: 12071338
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy in women with insufficient glucose control
Study: 6620013
Drug: Chest physical
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chest physical therapy (CPT) administered by a parent, regular twice daily basis
Study: 30526648
Drug: Buprenorphine 32
Normalized name: BUPRENORPHINE 32MG/0.64ML SA INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 32 mg
Study: 30526648
Drug: Buprenorphine 64
Normalized name: BUPRENORPHINE 64MG/0.18ML SA INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 64 mg
Study: 30526648
Drug: Buprenorphine 96
Normalized name: BUPRENORPHINE 96MG/0.27ML SA INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 96 mg
Study: 18372697
Drug: Nitroglycerin (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (0.3 mg sublingual administration)
Study: 9702435
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg three times a day with a mildly hypocaloric diet
Study: 31969443
Drug: Erector spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector spinae plane block (ESPB) with ropivacaine 0.5% and epinephrine (20 mL unilateral or 16 mL/side for bilateral)
Study: 31969443
Drug: Paravertebral nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paravertebral nerve block (PVB) with ropivacaine 0.5% and epinephrine (20 mL unilateral or 16 mL/side for bilateral)
Study: 31374368
Drug: 8-week home-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week home-based physical activity intervention (twice weekly supervised resistance training and unsupervised walking program)
Study: 20528005
Drug: Trans-resveratrol 2000
Normalized name: trans-resveratrol 3-β-glucoside
DrugBank: Polydatin (DB11263)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trans-resveratrol 2000 mg twice daily with standard breakfast
Study: 20528005
Drug: Trans-resveratrol 2000
Normalized name: trans-resveratrol 3-β-glucoside
DrugBank: Polydatin (DB11263)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trans-resveratrol 2000 mg twice daily with high-fat breakfast
Study: 20528005
Drug: Quercetin 500
Normalized name: quercetin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin 500 mg twice daily
Study: 20528005
Drug: 5% alcohol
Normalized name: ALCOHOL 0.75 TOPICAL CLOTH [75% Alcohol Wipes]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% alcohol 100 mL
Study: 20528005
Drug: Trans-resveratrol 2000
Normalized name: trans-resveratrol 3-β-glucoside
DrugBank: Polydatin (DB11263)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trans-resveratrol 2000 mg twice daily
Study: 16156492
Drug: Common Factors
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common Factors Therapy (CFT)
Study: 7772424
Drug: Ephedrine 0.6
Normalized name: pseudoephedrine 0.66 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 0.6 mg kg‐1 body weight
Study: 2185693
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B syrup 2,400 mg/day
Study: 2185693
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B syrup 1,200 mg/day
Study: 2185693
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B syrup 800 mg/day
Study: 2185693
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B syrup 400 mg/day
Study: 7444371
Drug: Hog mucosa
Normalized name: hog epithelia extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hog mucosa heparin
Study: 26795764
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list group receiving conventional orthopaedic therapy (n=42)
Study: 20671098
Drug: 10 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 weeks of drug therapy combined with behavioral intervention (pelvic‐floor muscle exercises, UI prevention strategies, delayed voiding)
Study: 20671098
Drug: 10 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 weeks of drug therapy combined with behavioral intervention
Study: 20671098
Drug: 10 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 weeks of drug therapy only
Study: 18313371
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg zopiclone (test)
Study: 18313371
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg zopiclone (reference)
Study: 15801925
Drug: Micafungin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin (150 mg/day)
Study: 15801925
Drug: Fluconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (200 mg/day)
Study: 27128532
Drug: One-quarter standard-dose
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-quarter standard-dose ticagrelor
Study: 30252571
Drug: Half standard-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half standard-dose ticagrelor
Study: 30252571
Drug: Standard-dose ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose ticagrelor
Study: 30252571
Drug: Ticagrelor groups
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor groups (all doses)
Study: 30252571
Drug: Half and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half and standard-dose ticagrelor
Study: 27762434
Drug: Oxycodone-naloxone
Normalized name: naloxone / oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone-naloxone
Study: 16148323
Drug: Structured interview
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured interview (Schedule for Affective Disorders and Schizophrenia for School‐aged Children‐Present and Lifetime Versions) administered by a trained interviewer before the initial physician visit
Study: 12133120
Drug: Alpha-2-adrenergic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-2-adrenergic agents and naltrexone (control group 2)
Study: 9918565
Drug: Dextromethorphan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan (50 mg DEM hydrobromide orally)
Study: 9918565
Drug: Quinidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (50 mg Qd sulfate orally)
Study: 2224916
Drug: Etretinate 25
Normalized name: etretinate 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etretinate 25 mg daily
Study: 26357943
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy-informed software application (Actissist) plus Treatment As Usual (TAU)
Study: 26357943
Drug: Symptom monitoring
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom monitoring software application (ClinTouch) plus Treatment As Usual (TAU)
Study: 21419704
Drug: AAV2‐GAD infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV2‐GAD infusions
Study: 9771860
Drug: 6 IU
Normalized name: Coenzyme Q10/Vitamin E 30 MG-6 IU Oral Capsule, Liquid Filled
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 IU GH twice daily from 2 days before to 7 days after the operation
Study: 7819101
Drug: Soluble interleukin‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble interleukin‐2 receptor (sIL‐2r)
Study: 7819101
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of elevated IL‐10 and sIL‐2r > 3000 U/ml
Study: 7819101
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IL‐10 with sIL‐2r
Study: 3046294
Drug: intravenous anisoylated
Normalized name: Anisoylated plasminogen streptokinase activator complex
DrugBank: Anistreplase (DB00029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous anisoylated plasminogen streptokinase activator complex (APSAC)
Study: 24206873
Drug: DCB (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCB (3 μg/mm²) followed by CoCr-stent
Study: 20847736
Drug: PDA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDA with self-monitoring software and daily feedback messages (PDA+FB)
Study: 18082667
Drug: 600 mcg
Normalized name: Biotin 600 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mcg of vaginal misoprostol every 6 h up to four doses
Study: 18082667
Drug: 400 mcg
Normalized name: Biotin 400 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mcg of vaginal misoprostol every 4 h up to five doses
Study: 16678205
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg QD (after switching from placebo)
Study: 11076429
Drug: Oral granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral granisetron plus i.v. dexamethasone
Study: 11076429
Drug: Intravenous ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ondansetron plus i.v. dexamethasone
Study: 9084348
Drug: Etidronate, 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate, 800 mg orally, once per day for 2 weeks of 15 weeks, repeated once.
Study: 9084348
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (without etidronate).
Study: 8210923
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg etodolac SR once a day for up to 52 weeks
Study: 8210923
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg etodolac SR once a day for up to 52 weeks
Study: 3730528
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg innovator product
Study: 3730528
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg generic product
Study: 3730528
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg solution
Study: 29757462
Drug: 200 g
Normalized name: PEG-200 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 g guava/day
Study: 29757462
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg synthetic vitamin C/day